9 Meters Biopharma Inc
OTC:NMTRQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
J
|
Jaya Tiasa Holdings Bhd
KLSE:JTIASA
|
MY |
|
Guangdong Goworld Co Ltd
SZSE:000823
|
CN |
|
Netplex Group Inc
OTC:NTPL
|
US |
|
Rio Paranapanema Energia SA
BOVESPA:GEPA3
|
BR |
|
Hubei Three Gorges Tourism Group Co Ltd
SZSE:002627
|
CN |
|
Electro Aco Altona SA
BOVESPA:EALT4
|
BR |
|
Shenzhen Etmade Automatic Equipment Co Ltd
SZSE:300812
|
CN |
|
S
|
Sport1 Medien AG
XHAM:EV4
|
DE |
|
Z
|
Zinzino AB
STO:ZZ B
|
SE |
|
H
|
Hainan Jingliang Holdings Co Ltd
SZSE:000505
|
CN |
9 Meters Biopharma Inc
Inventory
9 Meters Biopharma Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
9 Meters Biopharma Inc
OTC:NMTRQ
|
Inventory
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
9 Meters Biopharma Inc
Glance View
9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.
